← boardnext 2027-08
COAG
Hemab ApSdistress 2/10 · well-funded / low risk$49.090%today-1% from 52w high
Lead: Von Willebrand Disease (VWD)
Revenue
pre-revenue
Liquidity
$164M
Runway
1.9 yrs
Shares 1y
—
Price & events
+44.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+10.3%
1W
+68.4%
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
+44.4%
All
Overview
- Market Cap
- $2.29B
- Volume
- 6.66K
- 52 Week Range
- $24.98 – $49.39
- Total Shares
- 46.71M
- Float Shares
- 23.74M
- % Held by Insiders
- 10.78%
- % Held by Institutions
- 65.89%
- RVOL
- 0.02x
Pipeline stages · 2 programs
HMB-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Sutacimig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-07 Estimated 50% readout ~2027-08-15 | Phase 1/2 | HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) ( | Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3 | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 1/2 | HMB-001 | Glanzmann Thrombasthenia | — | active not recruiting |
| 2026-07 | Phase 2 | Sutacimig | Congenital Factor VII Deficiency | 18 | recruiting |
Catalyst news & presentations · 1
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $50 (+2% upside) · 5 analysts
- 2026-07-13JefferiesBuy
- 2026-07-13WedbushOutperform
- 2026-07-13HC Wainwright & Co.Buy
- 2026-06-26HC Wainwright & Co.Buy
- 2026-06-17HC Wainwright & Co.Buy
- 2026-05-26WedbushOutperform
Competitors — Von Willebrand Disease (VWD)
- none identified
Recent news
- 2026-07-20Hemab Therapeutics (NASDAQ:COAG) Hits New 12-Month High - What's Next? - MarketBeat
- 2026-07-18Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
- 2026-07-16Hemab Therapeutics Holdings, Inc. Common Stock (NASDAQ: COAG) Stock Price, News & Analysis - Kalkine
- 2026-07-15Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts - Seeking Alpha
- 2026-07-14Hemab Therapeutics reports positive Phase 2 sutacimig data - grafa.com
- 2026-07-14Hemab Therapeutics (COAG) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
- 2026-07-14Hemab Therapeutics: Strong HMB-002 Data Drive Higher Probability of Success and Lift Price Target from $36 to $46 with Buy Rating - TipRanks
- 2026-07-14Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress - The Manila Times
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.